Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
McKinsey
AstraZeneca
Moodys
Medtronic

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Litigation Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

See Plans and Pricing

« Back to Dashboard

Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

Docket   Start Trial Date Filed 2018-12-11
Court District Court, D. Delaware Date Terminated 2019-05-09
Cause 35:271 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand None Referred To
Parties EAGLE PHARMACEUTICALS, INC.; SLAYBACK PHARMA LLC
Patents 10,010,533; 9,265,831; 9,572,796; 9,572,797
Attorneys Eve H. Ormerod; John W. Shaw; Karen Elizabeth Keller; Nathan Roger Hoeschen; Neal C. Belgam
Firms Shaw Keller LLP; Smith, Katzenstein, & Jenkins LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 Complaint (“the ’797 patent”); and 10,010,533 (“the ’533 patent”) (collectively, “the Patents-in-Suit”). …COUNT IV – INFRINGEMENT OF U.S. PATENT NO. 10,010,533 UNDER 35 U.S.C. § 271(e)(2) … INFRINGEMENT OF U.S. PATENT NO. 10,010,533 94. Eagle incorporates…infringement of the ’831 patent, the ’796 patent, the ’797 patent, and the ’533 patent. (b…of Eagle’s U.S. Patent Nos. 9,265,831 (“the ’831 patent”); 9,572,796 (“the ’796 patent”); 9,572,797 (“ External link to document
0000-00-00 17 Redacted Document (“the ‘797 patent”); and 10,010,533 (“the ‘533 patent”) (collectively, the “patents-in-suit”), which …infringes U.S. Patent Nos. 9,265,831 (“the ‘831 patent”); 9,572,796 (“the ‘796 patent”); 9,572,797 (“… the patents-in-suit. Rather, Plaintiff’s complaint alleges that Slayback infringes the patents-in-suit…infringe any claim of the patents-in-suit. All of the independent claims of these patents require a pharmaceutically…equivalents to prove infringement of the patents-in-suit. “[W]hen a patent drafter discloses but declines to External link to document
0000-00-00 23 Redacted Document “’831 Patent”); 9,572,796 (the “’796 Patent”); 9,572,797 (the “’797 Patent”); and 10,010,533 (the “’… four patents listed in the Orange Book and covering the formulation of Belrapzo®. U.S. Patents 9,265,831…“’533 Patent”) (the “Patents-in-Suit”) list inventors Nagesh Palepu and Philip Buxton. Certain claims…Plaintiff Plausibly Pled that Slayback Infringes the Patents-in-Suit............8 3. … questions over the proper interpretation of a patent’s intrinsic record are “not suitable” and “particularly External link to document
0000-00-00 28 Memorandum Opinion the "#796 patent"), 9,572,797 (the "#797 patent"), and 10,010,533 (the "#533…equivalents of four patents: U.S. Patent Nos. 9,265,831 (the "#831 patent"), 9,572,796 …glycol in embodiments of the patented invention. See, e.g., #796 patent at 1:60-64, 4:34-47, 5:27-35,…;#533 patent"). See generally D.I. 1. Pending before me is Slayback's motion for judgment…manufacture and sell before the four asserted patents expire a bendamustine drug that is bioequivalent External link to document
0000-00-00 30 Patent/Trademark Report to Commissioner ;9,572,796 B2 ;9,572,797 B2 ;10,010,533 B2. (Attachments: # 1 Order granting Motion for Judgment on the… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,265,831 B2 ;…December 2018 9 May 2019 1:18-cv-01953 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 31 Memorandum Opinion the "#796 patent"), 9,572,797 (the "#797 patent"), and 10,010,533 (the "#533…equivalents of four patents: U.S. Patent Nos. 9,265,831 (the "#831 patent"), 9,572,796 …glycol in embodiments of the patented invention. See, e.g., #796 patent at 1 :60-64, 4:34-47, 5:27-35…;#533 patent"). See generally D.I. 1. Pending before me is Slayback's motion for judgment on…manufacture and sell before the four asserted patents expire a bendamustine drug that is bioequivalent External link to document
0000-00-00 4 Patent/Trademark Report to Commissioner B2 ;US 9,572,796 B2 ;US 9,572,797 B2 ;US 10,010,533 B2. (nmg) (Entered: 12/11/2018) 11 December 2018… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,265,831 B2…December 2018 9 May 2019 1:18-cv-01953 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
McKesson
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.